Literature DB >> 11679028

Influence of age and comedication on steady-state clonazepam serum level-dose ratios in Japanese epileptic patients.

E Yukawa1, M Satou, T Nonaka, M Yukawa, S Ohdo, S Higuchi, T Kuroda, Y Goto.   

Abstract

BACKGROUND: In antiepileptic drugs, the marked inter- and intrapatient variability of the level-dose ratio makes it difficult to predict serum concentrations from the administered per kg dose. It is therefore important to identify factors, such as age and comedication, that could contribute to this observed variability.
OBJECTIVE: To investigate the effect of age and comedication on clonazepam (CZP) level-dose (L/D) ratios.
METHOD: A retrospective evaluation of data from 137 epileptic patients who had received clonazepam.
RESULTS: The CZP L/D ratio increased slowly with age up to 15 years in patients on monotherapy. Associated antiepileptic therapy affected the CZP L/D ratio, which was significantly reduced in patients on polytherapy as compared to patients on monotherapy.
CONCLUSION: The study therefore suggests that routine monitoring of CZP serum levels is extremely useful, especially in the paediatric age group, and in patients who require associated antiepileptic medication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679028     DOI: 10.1046/j.1365-2710.2001.00372.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  2 in total

1.  Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring.

Authors:  Juseop Kang; Yoo-Sin Park; Shin-Hee Kim; Sang-Hyun Kim; Min-Young Jun
Journal:  Korean J Physiol Pharmacol       Date:  2011-04-30       Impact factor: 2.016

2.  Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children.

Authors:  Sven C van Dijkman; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2017-11-07       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.